Patents by Inventor Shih-Fen LIAO

Shih-Fen LIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL FORMULATIONS COMPRISING TOFACITINIB
    Publication number: 20210212931
    Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.
    Type: Application
    Filed: March 26, 2021
    Publication date: July 15, 2021
    Inventors: Chih-Ming Chen, Guang-Wei Lu, Ling-Ying Liaw, Fan-Lun Liu, Shih-Fen Liao, Chou-Hsiung Chen, Yu-Han Kao, Yu-Yin Chen
  • Topical formulations comprising tofacitinib
    Patent number: 10960006
    Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: March 30, 2021
    Assignee: TWi Pharmaceuticals, Inc.
    Inventors: Chih-Ming Chen, Guang-Wei Lu, Ling-Ying Liaw, Fan-Lun Liu, Shih-Fen Liao, Chou-Hsiung Chen, Yu-Han Kao, Yu-Yin Chen
  • TOPICAL FORMULATIONS COMPRISING TOFACITINIB
    Publication number: 20190231782
    Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.
    Type: Application
    Filed: January 22, 2019
    Publication date: August 1, 2019
    Inventors: Chih-Ming Chen, Guang-Wei Lu, Ling-Ying Liaw, Fan-Lun Liu, Shih-Fen Liao, Chou-Hsiung Chen, Yu-Han Kao, Yu-Yin Chen
  • Antibody-mediated anti-tumor activity induced by Reishi mushroom polysaccharides
    Patent number: 10307470
    Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW=˜35 kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-?-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.
    Type: Grant
    Filed: July 26, 2014
    Date of Patent: June 4, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Hsien-Yeh Hsu, Shih-Fen Liao, Chi-Hui Liang
  • ANTIBODY-MEDIATED ANTI-TUMOR ACTIVITY INDUCED BY REISHI MUSHROOM POLYSACCHARIDES
    Publication number: 20160166661
    Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW=˜35 kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-?-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.
    Type: Application
    Filed: July 26, 2014
    Publication date: June 16, 2016
    Inventors: Chi-Huey WONG, Chung-Yi WU, Hsien-Yeh HSU, Shih-Fen LIAO, Chi-Hui LIANG